Of the 30 patients, 10 men and 5 women (mean age 54.3 ± 1.6 years) received ezetimibe plus atorvastatin, while 13 men and 2 women (mean age 53.7 ± 2.8 years) received only atorvastatin. The combination treatment significantly reduced total cholesterol (percentage treatment difference −14.4 ± 6.5, 95% confidence interval [CI] −1.0 to −27.7; p = 0.041) and LDL cholesterol (LDL-C; percentage treatment difference −19.9 ± 6.1, 95% CI −7.4 to −32.4; p = 0.003) compared to atorvastatin monotherapy. 13 patients on combination treament achieved the National Cholesterol Education Program target for LDL-C as compared to 9 patients on atorvastatin monotherapy (p = 0.032). Significant reductions in very low-density lipoprotein cholesterol, triglyceride, ox-LDL and sICAM were observed with combination treatment compared to atorvastatin monotherapy. However, no significant change was seen in high-density lipoprotein cholesterol or hsCRP levels between the two groups.
INTRODUCTION
Coronary artery disease (CAD), which afflicts millions of people worldwide, has reached alarming proportions in India. It is estimated that about 52% of CAD deaths in the country occur among people below 70 years of age, whereas in Western countries, CAD is considered a disease of the aged. (1) The huge burden of CAD in India is due to the high prevalence of CAD risk factors in the population. Dyslipidaemia is a major modifiable risk factor for the development of CAD. (2) High total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG) levels, along with a low high-density lipoprotein cholesterol (HDL-C) level, typify the mixed dyslipidaemia prevalent in the Indian population. (3, 4) Several large clinical trials have reported that statins are efficacious in lowering LDL-C, as well as in preventing and reducing mortality due to cardiovascular events in patients with CAD. (5, 6) The beneficial effects of statins extend beyond their cholesterol-lowering properties. Its anti-inflammatory, antioxidant, antiproliferative and antiplatelet effects have been suggested to be responsible for the overall efficacy of the drug. (7) (8) (9) However, for every subsequent doubling of the statin dose, there is only a mean 6% incremental reduction in LDL-C, and this is also associated with a higher frequency of adverse effects. (10) The National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATP III) has recommended a minimum LDL-C reduction of 30%-40% for patients considered to be at moderate to very high risk for CAD, a goal that is not always achievable with monotherapy. (11) Reportedly, less than 60% of patients with CAD or CAD risk equivalents achieve NCEP goals for LDL-C with monotherapy. (12) To overcome the limited efficacy of single agents and reduce the risk of adverse effects, which are often dose-related, the concept of combination drug therapy with lipid-modifying agents having mechanisms of action that differ from but complement those of low dose statins has emerged as a potential strategy for the management of dyslipidaemia.
Ezetimibe, a selective inhibitor of cholesterol absorption from the small intestine, inhibits cholesterol absorption from the intestine by blocking the action of the cholesterol transporter, Niemann-Pick C1-Like 1 (NPC1L1) protein. (13) MeThODs A double-blind study was conducted to assess the effect of fixed dose combination of ezetimibe 10 mg plus atorvastatin 10 mg on lipid profile, oxidised low-density lipoprotein (ox-LDL), high-sensitivity C-reactive protein (hsCRP) and soluble intercellular cell adhesion molecule (sICAM) in dyslipidaemic patients with or at high risk of coronary artery disease, and compare it with atorvastatin 10 mg monotherapy. 30 patients were randomised to receive ezetimibe plus atorvastatin or atorvastatin once daily for four weeks.
treatment is superior to statin monotherapy. (10) However, additional reduction in LDL-C is variable and ranges between 6% and 20% across different studies. (14) While a majority of the studies on ezetimibe and statin combination therapy have focused primarily on its lipid-lowering efficacy, the superiority of combination treatment over statin monotherapy in terms of its effect on proinflammatory markers is still not well-established.
Some studies have reported that the combination of ezetimibe and statin is superior to treatment with statin alone for the reduction of high-sensitivity C-reactive protein (hsCRP). (13) (14) (15) However, a few others have noted that hsCRP, proinflammatory cytokines and adhesion molecules remain unchanged with the combination of ezetimibe and statin. (16, 17) To the authors' knowledge, only one previous open-label, non-comparative study has reported the lipid-lowering efficacy of ezetimibe monotherapy in Indian patients with familial hypercholesterolaemia. (18) 
MeThODs
This study was a randomised, double-blind, parallel group, All the patients were monitored for the development of adverse events during the study. They were evaluated at baseline and on follow-up visit using a symptom checklist. The study participants were provided the contact numbers of the investigators and asked to report any adverse event at the earliest.
Adverse events in individual patients were evaluated via patient interviews for the presenting symptoms, physical examination and laboratory investigations. Causality assessment was carried out using the World Health Organization-Uppsala Monitoring Centre criteria and Naranjo algorithm. (20) Data 
ResUlTs
A total of 58 patients who presented to the cardiology outpatient department were screened (after obtaining consent for screening), out of which 34 patients were found to satisfy the eligibility criteria. Of those eligible, four patients refused to participate in the study. Thus, 30 patients were enrolled in the study after written Table I ). Baseline hsCRP and sICAM were also not significantly different between the two groups.
In patients from the study group, TC decreased by 34.5% from 224.7 ± 11.6 mg/dL to 147.1 ± 11.1 mg/dL (percentage treatment difference −14.4 ± 6.5, 95% CI −1.0 to −27.7; p = 0.041), which was statistically significant when compared to the control arm in which the corresponding decrease was 20.1% from baseline (Table II) . Treatment with atorvastatin plus ezetimibe also led to a considerable reduction in LDL-C, which was reduced by 44.2%, (Table II) .
Serum AST, ALT, urea and creatinine were within the normal range both at baseline and at follow-up after four weeks of treatment, and there were no significant differences between the levels observed in the two groups (Table III ). The median serum hsCRP level of patients in the atorvastatin plus ezetimibe to 319 μg/mL, and the decrease was significant when compared to patients on atorvastatin monotherapy (p = 0.042) (Table III) .
Two patients in the study arm and one in the control arm complained of mild dyspepsia at follow-up, which was probably related to drug intake. The patients did not, however, discontinue the drug. None of the adverse events encountered in the study was serious.
DIsCUssION
The prevalence of dyslipidaemia is reported to be as high as 62% among urban Indian men, and a greater atherogenic role has been attributed to TC and LDL-C in the development of CAD. (3, 4, 21) Our study was carried out to evaluate the effect of provided LDL-C reduction equivalent to that of three dose titrations of the statin, (22) while in the Ezetimibe Add-on Statin for Effectiveness (EASE) trial, 10 mg of ezetimibe added to ongoing statin therapy led to 25% reduction in LDL-C levels compared to 2% reduction with the statin alone. (16) In addition, studies have reported that during a four-week treatment period, the degree of LDL-C reduction achieved by 40 mg/day of atorvastatin was comparable with that obtained by 10 mg/day of ezetimibe in combination with 10 mg/day of atorvastatin. (23) In our study, the proportion of patients achieving NCEP-ATP III LDL-C target levels with combination treatment was also similar to that of other reports. (24) (25) (26) (27) The decrease in LDL-C with combination treatment has been consistently reported across trials. Recently, the UK National
Institute for Health and Clinical Excellence (NICE) assessment group carried out a meta-analysis of shorter-term studies (less than 12 weeks in duration) comparing ezetimibe coadministered with statin therapy versus statin therapy alone. It showed that the addition of ezetimibe to statin therapy reduced LDL-C concentrations by 23.2% more than statin therapy alone, and this is consistent with our observation of an additional 20% reduction in LDL-C levels with combination treatment. (10) Every 1% decrease in LDL-C is associated with an approximate 1% decrease in CAD-related mortality. (26) Therefore, in our study, patients on combination therapy with atorvastatin plus ezetimibe presumably had an almost 20% lower risk of developing CADrelated events than those on atorvastatin monotherapy.
Elevated ox-LDL level has also been identified as a risk factor for the development of CAD. (27) Besides being a marker of oxidative stress, ox-LDL also increases the expression of adhesion molecules on endothelial cells, enhances monocyte chemotaxis and upregulates the genes of inflammatory mediators. (28, 29) Serum ox-LDL level decreased significantly in the patients of our study group when compared to those in the control group. However, our findings on serum ox-LDL differ from those of a recent study by Nozue et al, where significant change in ox-LDL level was not observed following the addition of ezetimibe to statin therapy. (30) The change in ox-LDL level observed with combination therapy in our study may possibly have been because we had controlled for confounders such as diet and lifestyle patterns. (31) No significant change in the HDL-C level was observed between the two groups in our study. This is in agreement with a study by Constance et al, where no statistically significant change in HDL-C was observed with the administration of a combination of ezetimibe 10 mg and simvastatin 40 mg for six weeks as compared to only atorvastatin 20 mg. (32) However, according to the NICE meta-analysis, the ezetimibe plus statin combination increases HDL-C levels only slightly. (10) It is possible that a significant change in HDL-C level was not observed in our study due to its short duration and the small number of participants.
Elevated serum hsCRP is associated with a higher risk of developing CAD. The effect of statins in patients with CAD or at high risk of developing CAD is reflected by a significant reduction in hsCRP. (33, 34) In our study, the difference in the median serum hsCRP levels of patients from the study and control groups was not statistically significant. This is consistent with a recent study by Gupta et al, where ezetimibe added to stable statin therapy for 12 weeks produced no significant effect on leptin, hsCRP, tumour necrosis factor-α or interleukin-6
concentrations. (35) In contrast, Ballantyne et al, who compared atorvastatin and ezetimibe combination treatment to atorvastatin alone, reported an overall larger reduction in hsCRP levels with the combination. Interestingly, the authors found that this effect was observed by adding ezetimibe 10 mg to a higher dose of atorvastatin (80 mg), but not with a lower dose of atorvastatin (10 mg) despite consistent LDL-C level lowering across the whole dosing range of atorvastatin. (36) Although currently available data suggests that ezetimibe may have a synergistic effect on hsCRP levels when combined with statins, (37) the mechanism of this effect and the interaction of ezetimibe with different statins still require clarification. It is possible that significant change in hsCRP was not observed in our study due to its short duration.
The role of sICAM in the pathogenesis of CAD has generated considerable interest in recent years. Elevated levels of sICAM, a biomarker for inflammation, generated from endothelial cells and leukocytes have been reported in patients with stable angina and acute coronary syndrome. (38, 39) There was significant reduction in the sICAM levels of patients treated with the combination as compared to those on atorvastatin monotherapy in our study.
It is possible that the reduction in sICAM with the combination therapy was associated with reductions in the level of ox-LDL, a mediator which is known to enhance the expression of cell adhesion molecules. (29, 40) Additionally, the anti-inflammatory effect could have been secondary to the LDL-C-lowering effect of the combination treatment.
Major safety concerns with statin therapy include the rare occurrence of serious muscle-related adverse events and the potential of elevated serum transaminases. A study on 4,558 patients receiving the ezetimibe-simvastatin combination concluded that the incidence of myopathy (0.04%) was no more common in these patients than that observed in 2,563 patients taking simvastatin alone (0.08%). In addition, there was no report of rhabdomyolysis in either group. (41) Furthermore, according to
Florentin et al, neither ezetimibe monotherapy nor combination treatment has been related to liver failure, the need for liver transplantation or death. (42) The FDC of atorvastatin plus ezetimibe in our study was well-tolerated, with a safety profile comparable to that of atorvastatin monotherapy. Mild dyspepsia was the only adverse event encountered in this study. There were no clinically significant alterations in AST, ALT, urea and creatinine levels in both patient groups. Our observations were in accordance with other studies that reported similar safety profiles for the ezetimibe-statin combination and statin monotherapy, even in special populations such as elderly patients and those with chronic kidney disease. (22, 43, 44) In conclusion, our study suggests that atorvastatin plus ezetimibe combination therapy has relatively better lipid-lowering and anti-inflammatory effects than atorvastatin monotherapy, with a comparable safety profile. To our understanding, this is likely the first randomised, double-blind, comparative trial of the combination in Indian patients with dyslipidaemia who have CAD or are at risk of developing CAD. The reduction of LDL-C with atorvastatin plus ezetimibe combination therapy in Indian patients, as observed in our study, was comparable to that observed in non-Indian patients of other races and ethnicities. (45) However, the limitations of our study, including a small sample size, short duration, underrepresentation of women and patients with diabetes mellitus in the study groups, and the fact that most of the patients were already on low-dose atorvastatin at study initiation, should be noted. Nevertheless, this pilot study may be useful in providing a background for further studies aiming at a comprehensive evaluation of the combination treatment in Indian patients.
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